What Is Active Surveillance for Prostate Cancer?

Active surveillance is a structured monitoring approach for confirmed low risk, localised prostate cancer, rather than immediate treatment. It involves regular PSA testing, periodic digital rectal exam, repeat biopsy, usually within a year of diagnosis and periodically after, and MRI monitoring to track any change. If monitoring shows the disease has progressed, treatment such as surgery or radiation follows. This is not the same as doing nothing, it is close, scheduled observation with a defined plan to act if needed.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “Active surveillance is often misunderstood as simply waiting and hoping. It is not. It is a defined protocol, PSA checks every few months, a repeat biopsy at a set point, MRI to track the tumour closely. For the right low risk case, this avoids the side effects of treatment a patient may never actually need. But the moment monitoring shows any sign of progression, we move to treatment without delay. It is surveillance with a clear trigger to act.”

Not every prostate cancer diagnosis is suitable for this approach, specific criteria determine candidacy.

• Low grade disease : A low Gleason score or grade group indicates cancer cells that appear less aggressive under the microscope, a key requirement.
• Low PSA and limited volume : A low PSA level combined with a small amount of cancer identified on biopsy supports the case for monitoring rather than treating.
• Confined to the prostate : The cancer must be localised, with no evidence of spread beyond the gland on imaging or examination.
• Personal preference matters too : Men wishing to avoid treatment side effects such as incontinence or erectile dysfunction, when appropriate, may prefer this route.

Identifying the right candidates for this approach is central to thoughtful prostate cancer treatment planning, where not every diagnosis warrants immediate intervention.

Active surveillance follows a defined schedule, not an open ended wait and see approach.

• Regular PSA testing : Checked roughly every three to six months, PSA trends over time are more informative than any single reading.
• Repeat biopsy : Typically performed within a year of the initial diagnosis, then periodically, to confirm the cancer has not become more aggressive.
• MRI monitoring : Imaging tracks the tumour’s size and characteristics between biopsies, adding another layer of surveillance.
• A clear trigger to act : Rising PSA, a higher grade found on repeat biopsy, or MRI changes prompt a move to active treatment.

This structured approach is directly relevant to understanding prostate cancer symptoms, since the disease being monitored is often entirely asymptomatic throughout.

Dr. Sandeep Nayak is a surgical oncologist with 24 years of experience and a fellowship in laparoscopic and robotic onco-surgery. His approach to active surveillance follows a strict monitoring protocol with defined triggers for treatment, ensuring that men on surveillance are genuinely being watched closely rather than simply advised to wait. This means clear communication about what monitoring involves and when treatment would become necessary.

Active surveillance works precisely because it is active, not passive. A defined schedule of testing, a clear point at which biopsy is repeated, and specific criteria that would prompt treatment give a patient genuine oversight of their disease rather than uncertainty. For the right low risk case, this protects a man from unnecessary treatment side effects while ensuring nothing progresses unnoticed.

References

1. Active surveillance protocols and outcomes in prostate cancer – National Library of Medicine
2. Comparing active surveillance and watchful waiting strategies – National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.